David Sinclair: GLP-1 Blindness Risk Is Real, and ALS May Be Reversible When a Harvard geneticist casually estimates that GLP-1 drugs may be causing 20,000 to 30,000 cases of sudden blindness per year in the US, then immediately pivots to say his lab's experimental therapy is being positioned to treat that very complication, you understand why longevity science has become the most watched and most confusing corner of medicine
They operate through fundamentally different biological pathways, which is why comparing them purely on "wrinkle outcomes" misses most of the picture
How it compares: MEDVi focuses on affordability and speed without compromising medical oversight
Reiner et al., 2018
At TrimRx, we believe that understanding the how and why of your treatment is just as important as the medication itself
This entry does not include dosing amounts, injection frequency, or cycle length information